The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma
Kriachok I.A., Kushchevyi E.V.
Summary. Multiple myeloma is a quite common disease accounting about 1% of all tumors and up to 10% of hemoblastoses and is currently considered as incurable disease, howewer modern antitumor therapy allows to richt long-term remission and as a result — a period of life without symptoms of disease. High-dose chemotherapy with autologous hematopoietic stem cells transplantation (HSCТ) or allogeneic HSCТ allows to achieve the best possible results of therapy. High-dose chemotherapy followed by autologous HSCТ is a standard option and justified as a first front-line therapy, improving the response obtained after induction therapy using new therapeutic agents. Allogeneic HSCТ in multiple myeloma patients is not a standard therapeutic approach, but with low intensity conditioning can be used for young patients with high risk if presence a related donor at transplantation centers which have sufficient experience of allogeneic HSCТ.
Leave a comment